@article{9d440af3db2f40a097699f6b4529c341,
title = "Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older - Reply",
author = "Bach, \{Richard G.\} and Cannon, \{Christopher P.\} and Blazing, \{Michael A.\}",
note = "Funding Information: Conflict of Interest Disclosures: Dr Bach has received grants from Merck, CSL Behring, and MyoKardia paid to his institution and personal fees for serving on clinical event committees from Amaron Bio, Novo Nordisk, and Pharmacosmos. Dr Cannon has received research grants from Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Janssen Pharmaceuticals, Merck, and Pfizer and personal fees for serving on advisory board from Aegerion Pharmaceuticals, Alnylam Pharmaceuticals, Amarin Corp, Amgen, Applied Therapeutics, Ascendia Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Corvidia Therapeutics, HLS Therapeutics, Innovent Biologics, Janssen Pharmaceuticals, Kowa Pharmaceuticals, Merck, Pfizer, and Sanofi. Dr Blazing has received grants from Merck and personal fees from Sanofi.",
year = "2020",
month = feb,
doi = "10.1001/jamacardio.2019.5241",
language = "English",
volume = "5",
pages = "235--236",
journal = "JAMA Cardiology",
issn = "2380-6583",
number = "2",
}